Lunai Bioworks Sues 10 Defendants Over Alleged Naked Short Selling Scheme
Event summary
- Lunai Bioworks filed an amended complaint against 10 defendants, including three FINRA-registered broker dealers, alleging a coordinated naked short selling scheme.
- The company claims the scheme resulted in failures to deliver on more than 81% of its outstanding shares between November 2025 and May 2026.
- On March 17, 2026, trading volume reached 15.3 times the total number of issued shares, with zero shares available to borrow in the institutional lending market.
- Lunai is seeking treble damages under the federal RICO statute and plans to add more defendants as its investigation continues.
The big picture
Lunai Bioworks' lawsuit highlights the ongoing issue of market manipulation through naked short selling, a practice that can distort stock prices and harm investors. The case also underscores the importance of regulatory oversight in maintaining market integrity, particularly for smaller biotech companies vulnerable to such schemes. The strategic implications extend beyond Lunai, as successful litigation could set a precedent for other firms facing similar challenges.
What we're watching
- Litigation Strategy
- Whether Lunai Bioworks can successfully prove its allegations and secure treble damages under the RICO statute.
- Market Impact
- How the ongoing litigation may affect investor confidence and trading activity in Lunai's stock.
- Regulatory Scrutiny
- The pace at which regulators may investigate similar naked short selling schemes in other biotech stocks.
Related topics